Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Kaletra-isentress Treatment Evaluation (KITE)

This study has been completed.
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Ighovwerha Ofotokun, Emory University Identifier:
First received: June 16, 2008
Last updated: November 25, 2014
Last verified: November 2014
Results First Received: June 7, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: HIV Infections
Interventions: Drug: Kaletra + Isentress
Drug: Pre-study antiretroviral regimen

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
All subjects were recruited from an urban outpatient HIV clinic (the Grady Infectious Diseases Program Out-patient Clinic, Atlanta, Georgia) between June 2008 and January 2011.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Subjects were excluded if they were on medications that could interact with Protease inhibitors, had an active opportunistic infection, had renal and/or hepatic impairment, or were pregnant. Hepatitis B virus (HBV) co-infected patients receiving a nucleotide analogue for both HIV and HBV suppression were also excluded from enrollment.

Reporting Groups
Kaletra + Isentress Switched to Kaletra + Isentress
Standard HAART Pre-study standard HAART regimen

Participant Flow:   Overall Study
    Kaletra + Isentress   Standard HAART
STARTED   40   20 
COMPLETED   39   19 
Withdrawal by Subject                1                0 
Lost to Follow-up                0                1 

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Kaletra + Isentress switched to Kaletra + Isentress
Standard HAART Pre-study standard HAART regimen
Total Total of all reporting groups

Baseline Measures
   Kaletra + Isentress   Standard HAART   Total 
Overall Participants Analyzed 
[Units: Participants]
 40   20   60 
[Units: Participants]
<=18 years   0   0   0 
Between 18 and 65 years   40   20   60 
>=65 years   0   0   0 
[Units: Years]
Mean (Standard Deviation)
 46  (9)   48  (12)   47  (10) 
[Units: Participants]
Female   14   8   22 
Male   26   12   38 
Region of Enrollment 
[Units: Participants]
United States   40   20   60 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Plasma Viral Loads (HIV-1 RNA PCR)   [ Time Frame: baseline to week 48 ]

2.  Secondary:   To Compare Plasma Triglyceride Levels at 48 Weeks Between LPV/r + RAL and Standard HAART Treated Subjects   [ Time Frame: 48 weeks ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The findings of the KITE study should be interpreted in the context of a pilot study with a small sample size. Furthermore, adverse effects were self-reported, and the lack of blinding may have introduced biases in the collection of the data.

  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Dr. Igho Ofotokun
Organization: Emory University School of Medicine
phone: 404-616-0659

Publications of Results:

Responsible Party: Ighovwerha Ofotokun, Emory University Identifier: NCT00700115     History of Changes
Other Study ID Numbers: IRB00006876
KITE-6876 ( Other Identifier: Other )
Study First Received: June 16, 2008
Results First Received: June 7, 2012
Last Updated: November 25, 2014